<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05791916</url>
  </required_header>
  <id_info>
    <org_study_id>3456/20</org_study_id>
    <nct_id>NCT05791916</nct_id>
  </id_info>
  <brief_title>Novel Biomarkers in Patients With Acute Myocardial Infarction</brief_title>
  <acronym>CLEAR-AMI</acronym>
  <official_title>Clinical, Laboratory and Echocardiographic Assessment of Biomarkers in Patients With Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aristotle University Of Thessaloniki</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to investigate the clinical value of novel biomarkers and echocardiographic&#xD;
      indices, including myocardial work parameters, in patients with first acute myocardial&#xD;
      infarction. The relationship between novel echocardiographic indices with clinical data,&#xD;
      biochemical data in different myocardial infarction types will be attempted. Prognostic&#xD;
      implications of those indices will be explored.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective registry designed to evaluate and explore novel associations and&#xD;
      prognostic tools in patients with first Acute Myocardial Infarction (AMI) with or without ST&#xD;
      elevation, as defined by the Fourth Universal Definition of Myocardial Infarction. All&#xD;
      eligible adult patients admitted to the Department of Cardiology at AHEPA University General&#xD;
      Hospital of Thessaloniki with AMI will be invited to participate.&#xD;
&#xD;
      Following revascularization, a complete and comprehensive medical interview will be conducted&#xD;
      for each patient, during which demographic characteristics, baseline medical history, medical&#xD;
      therapy upon admission and discharge, primary aetiology, and clinical presentation of&#xD;
      hospitalization will be recorded. Laboratory data will be collected on admission and during&#xD;
      hospitalization, including complete blood count, biochemical control, coagulation mechanism&#xD;
      control, hormonal control, lipid profile including Lp(a), HbA1c, N-terminal pro-B-type&#xD;
      natriuretic peptide plasma, higher-peak value of HsTnT, IL-6, and suPAR levels on admission.&#xD;
&#xD;
      A comprehensive transthoracic echocardiographic assessment (TTE) will be performed within&#xD;
      24-48 hours from revascularization to evaluate the cardiac function of patients. The TTE will&#xD;
      include 2-dimensional-speckle-tracking analysis of all cardiac chambers and non-invasive&#xD;
      calculation of myocardial work of the left and right ventricles. The clinical value and&#xD;
      prognostic implications of these echocardiographic indices will also be investigated during&#xD;
      follow-up.&#xD;
&#xD;
      The primary objective is to identify novel prognostic tools by examining the association&#xD;
      between echocardiographic indices, clinical, and biochemical data. The study aims to&#xD;
      contribute to a better understanding of the pathophysiology of this condition and the&#xD;
      development of effective management strategies. By comprehensively assessing the clinical,&#xD;
      biochemical, and echocardiographic features of patients with AMI, this study will help to&#xD;
      establish a foundation for developing targeted and effective treatments for AMI patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2022</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">December 10, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>18 Months</target_duration>
  <primary_outcome>
    <measure>Relationship between clinical, laboratory and echocardiographic biomarkers</measure>
    <time_frame>18 months</time_frame>
    <description>Clinical, laboratory, conventional and novel echocardiographic parameters including among others left ventricular myocardial work indices, right ventricular myocardial work indices, 2-dimensional speckle-tracking analysis of all cardiac chambers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relationship between clinical, laboratory, and echocardiographic biomarkers with short- and long-term prognosis of patients</measure>
    <time_frame>18 months</time_frame>
    <description>Clinical, laboratory, and echocardiographic parameters including among others left ventricular myocardial work indices, right ventricular myocardial work indices, 2-dimensional speckle-tracking analysis of all cardiac chambers.&#xD;
Different units of measure in this outcome do not represent different outcome measures. All clinical, laboratory and echocardiographic measurements will be evaluated separately in their own unit of measurement to assess potential prognostic biomarkers in patients with acute myocardial infarction. This does not render the measurement of each parameter a different clinical outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>18 months</time_frame>
    <description>Death by any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>18 months</time_frame>
    <description>Death directly attributed to the primary disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Failure hospitalization</measure>
    <time_frame>18 months</time_frame>
    <description>Hospitalization due to heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Coronary syndrome</measure>
    <time_frame>18 months</time_frame>
    <description>Acute Coronary Syndrome including Myocardial Infarction with or without ST elevation and Unstable Angina</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>18 months</time_frame>
    <description>Composite of all-cause mortality, non-fatal acute coronary syndrome and heart failure hospitalization</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Biochemical Dysfunction</condition>
  <eligibility>
    <study_pop>
      <textblock>
        This study will enroll consecutive patients admitted to the First Department of Cardiology&#xD;
        of AHEPA University General Hospital, Aristotle University of Thessaloniki, Thessaloniki,&#xD;
        Greece with first Acute Myocardial Infarction with or without ST elevation, as defined by&#xD;
        the Fourth Universal Definition of Myocardial Infarction.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients older than 18 years&#xD;
&#xD;
          2. Patients acutely admitted at the Department of Cardiology of AHEPA University General&#xD;
             Hospital, Thessaloniki, Greece with Acute Myocardial Infarction, as those are defined&#xD;
             by the Fourth Universal Definition of Myocardial Infarction.&#xD;
&#xD;
          3. Patients without known history of coronary artery disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients &lt; 18 years old at time of coronary angiography&#xD;
&#xD;
          2. Patients with a previous history of coronary artery disease and/or prior&#xD;
             revascularization&#xD;
&#xD;
          3. Inability or refusal to provide informed consent&#xD;
&#xD;
          4. Subject is pregnant and/or breastfeeding or intends to become pregnant during the&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonios Ziakas, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>School of Medicine, Aristotle University of Thessaloniki</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christos Savopoulos, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>School of Medicine, Aristotle University of Thessaloniki</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vasileios Kamperidis, MD, MSc, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>School of Medicine, Aristotle University of Thessaloniki</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stylianos Daios, MD, MSc</last_name>
    <phone>6947529606</phone>
    <phone_ext>+30</phone_ext>
    <email>stylianoschrys.daios@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vasileios Anastasiou, MD, MSc</last_name>
    <phone>6978223907</phone>
    <phone_ext>+30</phone_ext>
    <email>vasianas44@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AHEPA University Hospital, Thessaloniki, Greece</name>
      <address>
        <city>Thessaloníki</city>
        <state>Central Macedonia</state>
        <zip>54621</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stylianos Daios, MD, MSc</last_name>
      <phone>6947529606</phone>
      <phone_ext>+30</phone_ext>
      <email>stylianoschrys.daios@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Vasileios Anastasiou, MD, MSc</last_name>
      <phone>6978223907</phone>
      <phone_ext>+30</phone_ext>
      <email>vasianas44@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>AHEPA University Hospital, Thessaloniki, Greece</name>
      <address>
        <city>Thessaloníki</city>
        <state>Central Macedonia</state>
        <zip>54621</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stylianos Daios, MD, MSc</last_name>
      <phone>+306947529606</phone>
      <phone_ext>+30§</phone_ext>
      <email>stylianoschrys.daios@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Vasileios Anastasiou, MD, MSc</last_name>
      <phone>6978223907</phone>
      <phone_ext>+30</phone_ext>
      <email>vasianas44@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 18, 2023</study_first_submitted>
  <study_first_submitted_qc>March 18, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2023</study_first_posted>
  <last_update_submitted>March 30, 2023</last_update_submitted>
  <last_update_submitted_qc>March 30, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aristotle University Of Thessaloniki</investigator_affiliation>
    <investigator_full_name>Stylianos Daios</investigator_full_name>
    <investigator_title>Cardiology Fellow</investigator_title>
  </responsible_party>
  <keyword>Acute Coronary Syndrome</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Echocardiography</keyword>
  <keyword>Myocardial Work</keyword>
  <keyword>Biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

